S-1: Bionano Genomics Launches Public Offering Amid Going Concern Warning

Bionano Genomics, Inc. announces a public offering of up to 2,032,520 shares of common stock, pre-funded warrants, and accompanying Series E and F warrants, aiming to raise approximately $9.0 million in net proceeds for working capital and general corporate purposes, while also disclosing a going concern risk.

Summary

• Bionano Genomics is offering up to 2,032,520 shares of common stock, or pre-funded warrants in lieu of common stock for certain purchasers, at an assumed combined public offering price of $4.92 per share and accompanying Warrants, based on the September 10, 2025 closing price.
• Each share of common stock or pre-funded warrant is being sold together with one Series E Warrant and one Series F Warrant.
• Pre-Funded Warrants have an exercise price of $0.0001 per share and are immediately exercisable, expiring when fully exercised.
• Series E and F Warrants have an assumed exercise price of $4.92 per share and will be exercisable upon stockholder approval (or immediately if 'Pricing Conditions' are met); Series E Warrants expire in five years, and Series F Warrants expire in 18 months from the Initial Exercise Date.
• The company expects to receive approximately $9.0 million in net proceeds from this 'best efforts' offering, after deducting placement agent fees and estimated offering expenses.
• An additional $20.0 million could be raised if all Warrants issued in this offering are exercised in cash.
• The company's common stock is listed on the Nasdaq Capital Market under the symbol BNGO; however, no public trading market is expected to develop for the Pre-Funded Warrants or Warrants.
• Bionano Genomics provides genome analysis solutions, including Optical Genome Mapping (OGM) systems (Saphyr and Stratys), the Ionic Purification system, and VIA software for data analysis and interpretation.
• Through its Bionano Laboratories business, the company offers OGM-based diagnostic testing services for conditions like facioscapulohumeral muscular dystrophy type 1 (FSHD1), hematologic malignancies, and preand post-natal structural variations, having phased out neurodevelopmental disorder (NDD) testing services in 2024.
• The company has expanded its genomic solutions through acquisitions of Lineagen (August 2020), BioDiscovery (October 2021), and Purigen (November 2022).

Sentiment

Score: 3

Explanation: The filing details a necessary capital raise to address liquidity, which is a short-term positive. However, the explicit 'going concern' warning, a history of multiple reverse stock splits, and the 'best efforts' nature of the offering highlight severe underlying financial distress and significant ongoing challenges. The substantial potential for dilution for existing shareholders and the contingent exercisability of warrants further contribute to a negative outlook.

Positives

• The offering aims to secure additional capital for working capital and general corporate purposes, providing immediate liquidity.
• Bionano Genomics has a clear mission to transform genome analysis through its comprehensive OGM solutions, diagnostic services, and software.
• The company boasts a broad product portfolio, including advanced OGM systems (Saphyr and Stratys), the Ionic Purification system, and the VIA software, which integrates various genomic data types.
• OGM technology has demonstrated superior performance over traditional cytogenetic methods and can identify structural variations not detectable by current gene sequencing solutions.
• Strategic acquisitions of Lineagen, BioDiscovery, and Purigen have expanded the company's capabilities and market reach, positioning it as a full-suite genomic solutions provider.
• There is a potential for significant additional proceeds of approximately $20.0 million if all Warrants issued in this offering are exercised in cash.

Negatives

• The company explicitly states a risk regarding its 'ability to continue as a going concern within 12 months,' indicating severe financial instability.
• The offering is a 'best efforts' offering with no minimum amount of securities required to be sold, meaning the company may not raise sufficient capital to address its financial needs.
• There is no established public trading market for the Warrants or Pre-Funded Warrants, which will severely limit their liquidity.
• The Warrants are speculative in nature, and there is no assurance that their market value will equal or exceed their respective public offering prices, or that it will ever be profitable for holders to exercise them.
• The exercisability of the Warrants is contingent on future stockholder approval, which is not guaranteed, potentially rendering them valueless.
• Management has broad discretion in the application of the net proceeds, and there is a risk that these funds may not be used effectively.
• The company has a history of failing to comply with Nasdaq's minimum bid price requirement, necessitating multiple reverse stock splits, which are typically dilutive for existing shareholders.
• The company does not intend to pay dividends, meaning any return to investors relies solely on potential increases in the stock price.
• The offering introduces significant potential for dilution for existing shareholders from the issuance of new shares and the future exercise of warrants.
• Covenants restrict the company from entering into variable rate financings for one year and other equity financings for 30 days post-closing, potentially limiting future capital-raising flexibility.

Risks

• Ability to improve margins, extend cash runway, and reach a potential pathway to profitability.
• Ability to continue as a going concern within 12 months, requiring cost management and significant additional financing.
• Risk that the 'best efforts' offering may not raise the amount of capital required for business plans, including near-term operations.
• Failure to comply with Nasdaq's continued listing requirements could lead to delisting, adversely affecting stock price, liquidity, and ability to obtain financing.
• Management's broad discretion in the use of net proceeds may result in ineffective allocation of funds.
• Absence of a public trading market for the Warrants and Pre-Funded Warrants limits their liquidity.
• Warrants are speculative; there is no assurance that the market price of common stock will ever equal or exceed the exercise price.
• Warrants are not exercisable until Warrant Stockholder Approval is obtained (unless Pricing Conditions are met), which is not guaranteed and could render them valueless.
• Potential for significant dilution to existing shareholders from the issuance of shares and exercise of Warrants and Pre-Funded Warrants.
• Introduction of competitive technologies or improvements in existing technologies could negatively impact the company's market position.
• Reliance on third-party contract sales organizations, suppliers, and manufacturers poses operational risks.
• Ability to attract and retain key scientific or management personnel is crucial for business success.
• Accuracy of estimates regarding expenses, future revenues, reimbursement rates, capital requirements, and needs for additional financing.
• Impact of adverse geopolitical and macroeconomic developments (e.g., bank failures, conflicts, inflation, supply chain issues) on business and operations.
• Ability to realize the anticipated benefits and synergies of prior and any future acquisitions or other strategic transactions.
• Ability to attract collaborators and strategic partnerships is essential for growth.
• Challenges in driving OGM adoption by potential customers for routine use in genomic analysis.
• Uncertainty regarding the impact and utility of Category I CPT codes to accelerate or increase the adoption of OGM.
• Purchasers who enter into a securities purchase agreement may have rights not available to other purchasers.
• Restrictions on subsequent equity sales for 30 days and variable rate transactions for one year following the closing date, with certain exceptions.

Future Outlook

The company aims to improve its margins, extend its cash runway, and achieve profitability. It plans to continue driving the adoption of Optical Genome Mapping (OGM) by potential customers for routine use in genomic analysis, anticipating that Category I CPT codes will accelerate this adoption. Bionano Genomics expects continued research, presentations, and publications to highlight OGM's utility compared to traditional cytogenetics. The Stratys system and VIA software are expected to increase throughput and simplify OGM data analysis. The company also intends to further deploy new products and applications for its technology platforms and anticipates future business growth. However, it acknowledges that if additional financing is not obtained, it may seek relief under applicable insolvency laws.

Management Comments

• "We believe we have transformed our business from an instrument company to a provider of a full suite of genomic solutions."
• "We believe that these acquisitions, along with internal investments in research and development and the build out of our commercial teams, have positioned us well to provide solutions to our customers that we believe will make OGM the standard cytogenetic technique for structural variant analysis."

Industry Context

Bionano Genomics operates in the rapidly evolving genome analysis market, with a core focus on Optical Genome Mapping (OGM). The company positions OGM as a superior and complementary technology to traditional cytogenetic methods (like karyotyping, FISH, Southern blot, and CMA) and even next-generation sequencing (NGS) for detecting structural variations. Its strategy of acquiring companies like Lineagen (diagnostic services), BioDiscovery (software), and Purigen (nucleic acid purification) reflects a broader industry trend towards offering integrated, end-to-end genomic solutions rather than standalone instruments. The mention of Category I CPT codes indicates the increasing importance of standardized reimbursement in the diagnostics sector, which is critical for broader market adoption of advanced genomic technologies.

Comparison to Industry Standards

• Optical Genome Mapping (OGM) has been shown to outperform current gold standard cytogenetic methods, including karyotyping, fluorescence in-situ hybridization (FISH), Southern blot, and chromosomal microarray (CMA), for the detection of structural variations (SVs).
• OGM has also been shown to identify structural changes in chromosomes that cannot be identified using current commercially available gene sequencing solutions.

Corporate Governance

Legal Proceedings

• No action, suit, inquiry, notice of violation, proceeding or investigation is pending or, to the knowledge of the Company, threatened against or affecting the Company, any Subsidiary or any of their respective properties that would result in a Material Adverse Effect or challenge the legality, validity or enforceability of any Transaction Document or the Securities.
• Neither the Company nor any Subsidiary, nor any director or officer thereof, is or has been the subject of any Action involving a claim of violation of or liability under federal or state securities laws or a claim of breach of fiduciary duty.
• There has not been, and to the knowledge of the Company, there is not pending or contemplated, any investigation by the Commission involving the Company or any current or former director or officer of the Company.
• The Commission has not issued any stop order or other order suspending the effectiveness of any registration statement filed by the Company or any Subsidiary under the Exchange Act or the Securities Act.

Related Party Transactions

• On April 13, 2023, the company entered into a Purchase Agreement with David Barker, the Chair of the Company's board of directors, to issue and sell one share of Series A Preferred Stock for $100.00.

Stakeholder Impact

• Shareholders: Will experience significant dilution from the issuance of new common stock and the potential exercise of warrants. The 'going concern' warning indicates a high risk to their investment, with returns solely dependent on future stock price appreciation as no dividends are planned.
• Employees: While not directly mentioned, the 'going concern' risk could create uncertainty regarding job security and future compensation if the company's financial health does not improve.
• Customers: The capital raise is intended to support working capital and general corporate purposes, which could enable continued investment in product development and service delivery for OGM solutions, diagnostic services, and software.
• Creditors: The additional capital from the offering may improve the company's short-term liquidity, potentially enhancing its ability to meet existing debt obligations, but the 'going concern' warning signals ongoing financial risk.

Next Steps

• Seek Warrant Stockholder Approval promptly, and in no event later than 90 days after the Closing Date, for the issuance of shares upon exercise of the Warrants.
• If Warrant Stockholder Approval is not obtained at the first meeting, call a stockholder meeting every 90 days thereafter until approval is received or the Warrants are no longer outstanding.
• Apply to list all of the Shares and Warrant Shares on the Nasdaq Capital Market and promptly secure their listing.
• Maintain the listing or quotation of the Common Stock on the Trading Market and comply with all listing and maintenance requirements.
• Use commercially reasonable efforts to keep a registration statement effective for the issuance or resale of the Warrant Shares during the term of the Warrants.
• Utilize the net proceeds from the offering for working capital and general corporate purposes.

Key Dates

Recommendation

The explicit disclosure of a 'going concern' risk within 12 months is a critical red flag, indicating severe financial instability. The 'best efforts' nature of the offering means the company may not secure sufficient capital, and even if it does, the substantial dilution from the new shares and warrants will significantly impair existing shareholder value. The history of multiple reverse stock splits and frequent capital raises further underscores a pattern of financial distress and value erosion. Given these profound risks and the uncertainty surrounding the company's long-term viability, a seasoned investor would likely recommend a strong sell.

Keywords

Bionano Genomics, BNGO, Public Offering, Common Stock, Pre-Funded Warrants, Series E Warrants, Series F Warrants, Capital Raise, Nasdaq, Optical Genome Mapping, OGM, Genomic Analysis, Biotechnology, Life Sciences, Diagnostics, Structural Variation, Cytogenetics, Saphyr, Stratys, VIA Software, Purigen, BioDiscovery, Lineagen, Going Concern, Dilution, Risk Factors, SEC Filing, S-1